Sana Biotechnology Schedules June 2025 Investor Conference Presentations to Update on Engineered Cell Therapy Pipeline
核心洞察
Sana Biotechnology will present at two major investor conferences in June 2025, including the Jefferies (搜索) Global Healthcare Conference and Goldman Sachs (搜索) 46th Annual Global Healthcare Conference.
The presentations will feature business overviews and updates on the company's engineered cell therapy programs focused on treating diabetes (搜索), autoimmune diseases, and cancer.
The company is developing innovative therapies including UP421 for diabetes (搜索) and SC291 for autoimmune disorders (搜索), with key clinical data expected in 2025.
Sana Biotechnology announced it will present at two prominent investor conferences in June 2025, providing updates on its engineered cell therapy pipeline that aims to transform treatment approaches for diabetes (搜索), autoimmune diseases, and cancer.
The Seattle-based company will deliver presentations at the Jefferies (搜索) Global Healthcare Conference on June 4, 2025, at 2:35 p.m. ET, followed by the Goldman Sachs (搜索) 46th Annual Global Healthcare Conference on June 10, 2025, at 8:40 a.m. ET. Both presentations will feature business overviews and program updates, with webcasts accessible through the company's investor relations website.
Engineered Cell Therapy Platform
Sana Biotechnology focuses on creating engineered cells as medicines for patients, with a vision of repairing and controlling genes, replacing missing or damaged cells, and making therapies broadly available. The company operates through multiple locations including Seattle, Cambridge, South San Francisco, and Bothell.
The company's pipeline includes several promising candidates currently in development. UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, represents a potential breakthrough for diabetes (搜索) treatment. Initial results from a first-in-human study demonstrated the ability to safely administer this therapy to patients without immunosuppression.
Clinical Pipeline Progress
SC291, Sana's CD19 (搜索)-targeted allogeneic CAR-T candidate, is being evaluated for patients with B-cell mediated autoimmune disorders (搜索) and has received FDA Fast Track Designation for systemic lupus erythematosus (搜索) treatment. The company expects data from phase 1 studies using SC291 for autoimmune disorders in 2025.
Additionally, SC262 is under investigation for patients with relapsed/refractory B-cell malignancies (搜索), with clinical data also anticipated in 2025. These programs utilize Sana's ex vivo HIP and in vivo fusogen platforms to develop next-generation cell therapies.
Investment Context
The upcoming investor presentations come at a critical time for Sana Biotechnology as the company advances multiple clinical programs. The webcasts will be available for replay for 30 days following each conference, allowing investors to access detailed updates on the company's progress and strategic direction.
Sana's approach to engineered cell therapy represents a potentially transformative approach to treating complex diseases, with the company positioning itself to address significant unmet medical needs across multiple therapeutic areas through its innovative platform technologies.